Drug Trial News

RSS

Researchers to initiate Crenezumab clinical trial to treat Alzheimer's

After an announcement by federal officials approving clinical trials for the drug Crenezumab, researchers searching for a way to treat Alzheimer's Disease are gearing up for a rare study that will allow them to test a therapy for a genetically predestined disease -- before its onset.

23 May 2012

New clinical trial to evaluate HSP90 inhibitor plus hormonal therapy for breast cancer

Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. As an integral part of this system, heat shock protein 90 (HSP90) has been shown to help malignant cells accommodate the genetic changes and profound disturbances in normal biology that occur in cancers.

23 May 2012

HVTN opens enrollment in GeoVax’s GM-CSF adjuvanted vaccine Phase 1 trial for HIV

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that the NIH-funded HIV Vaccine Trials Network (HVTN) has opened enrollment for a Phase 1 trial for the company's second-generation HIV vaccine.

23 May 2012

Daily use of vitamin C by smoking pregnant woman improves pulmonary function in babies

Vitamin C supplementation in pregnant women who are unable to quit smoking significantly improves pulmonary function in their newborns, according to a new study.

23 May 2012

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma

Boehringer Ingelheim announced today results from a Phase II study evaluating the investigational compound tiotropium delivered once-daily via the Respimat Inhaler in adolescents with symptomatic, moderate persistent asthma.

23 May 2012

Benefits of ICS treatment vary among children with differing demographic, clinical characteristics

A further analysis of a previously published National Heart, Lung, and Blood Institute (NHLBI) funded study of children with mild persistent asthma reports the relative benefits of inhaled corticosteroid (ICS) treatment varies among children with differing demographic and clinical characteristics.

23 May 2012

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.

23 May 2012

Combination therapy does not reduce mortality rates associated with severe sepsis

Frank M. Brunkhorst, M.D., of Friedrich-Schiller University, Jena, Germany, and colleagues conducted a study to compare the effect of the antibiotics moxifloxacin and meropenem with the effect of meropenem monotherapy on sepsis-related organ dysfunction.

22 May 2012

Gattex may represent new treatment approach for short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported the presentation of data at the Digestive Disease Week (DDW) meeting held May 19-22 in San Diego.

22 May 2012

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.

22 May 2012

Bayer’s Nexavar Phase 3 trial on NSCLC does not meet primary endpoint

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial evaluating Nexavar (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.

22 May 2012

New research reveals effective treatments for gastrointestinal conditions

New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.

22 May 2012

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.

22 May 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012

AltheRx reports positive Phase II results of Solabegron for OAB

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the American Urological Association Annual Meeting (Abstract # 520).

21 May 2012

SERVE-HF study on effect of CSA treatment for stable heart failure enrolls 1,000th participant

SERVE-HF, the largest study to investigate if treatment of predominant central sleep apnea (CSA) improves survival and outcomes of patients with stable heart failure, has enrolled its 1,000th participant. The study, sponsored by ResMed Ltd., is the largest of its kind. This milestone brings the SERVE-HF study, which began in 2008, one step closer to its target of approximately 1,250 participants.

From ResMed Corp 21 May 2012

Ipsen, Active Biotech complete half of planned recruitment in tasquinimod phase III study for CRPC

Active Biotech and Ipsen today announced that recruitment to the global, pivotal, randomized, double-blind, placebo-controlled phase III study of tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC) has reached an inclusion of 600 patients, half of the planned accrual.

21 May 2012

Hypertonic saline does not reduce rate of pulmonary exacerbations in young children with CF

Margaret Rosenfeld, M.D., M.P.H., of Seattle Children's Hospital, and colleagues conducted a study to examine if hypertonic saline would reduce the rate of pulmonary exacerbations in children younger than 6 years of age with cystic fibrosis.

21 May 2012

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels.

21 May 2012

Oxytocin increases brain activations in children and adolescents with ASD

Preliminary results from an ongoing, large-scale study by Yale School of Medicine researchers shows that oxytocin - a naturally occurring substance produced in the brain and throughout the body- increased brain function in regions that are known to process social information in children and adolescents with autism spectrum disorders (ASD).

21 May 2012

Drug Trial News

Researchers to initiate Crenezumab clinical trial to treat Alzheimer's

New clinical trial to evaluate HSP90 inhibitor plus hormonal therapy for breast cancer

HVTN opens enrollment in GeoVax’s GM-CSF adjuvanted vaccine Phase 1 trial for HIV

Daily use of vitamin C by smoking pregnant woman improves pulmonary function in babies

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma

Benefits of ICS treatment vary among children with differing demographic, clinical characteristics

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Combination therapy does not reduce mortality rates associated with severe sepsis

Gattex may represent new treatment approach for short bowel syndrome

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

Bayer’s Nexavar Phase 3 trial on NSCLC does not meet primary endpoint

New research reveals effective treatments for gastrointestinal conditions

Enrollment complete in Xencor, MorphoSys’ MOR208 phase 1 trial for CLL

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

AltheRx reports positive Phase II results of Solabegron for OAB

SERVE-HF study on effect of CSA treatment for stable heart failure enrolls 1,000th participant

Ipsen, Active Biotech complete half of planned recruitment in tasquinimod phase III study for CRPC

Hypertonic saline does not reduce rate of pulmonary exacerbations in young children with CF

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Oxytocin increases brain activations in children and adolescents with ASD

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News